September 10, 2024
Maryland Matters
Danielle J. Brown
Excerpt:
“The board early this summer selected six drugs for “cost review” that could be subject to the new procedures approved Tuesday, which would use a variety of methods to bring down costs for medications that pose an “affordability challenge.” One of those could be the upper payment limit.
Vincent DeMarco, president of Maryland Health Care for All who wants to expand the authority of PDAB, is “thrilled” at the decision.
“It is really a tremendous step forward in making high cost drugs more affordable, first for state and local governments, and then hopefully soon for all Marylanders,” he said.”
Read the full article at Maryland Matters.org
Last modified: September 25, 2024
